Millions of Americans are making a decision that a sweeping new body of research now shows is increasingly temporary: stopping their GLP-1 medication.
A study reported by ScienceDaily on June 16–17, 2026 — based on research presented at ENDO 2026, the Endocrine Society's annual meeting in Chicago — analyzed Komodo Health U.S. claims data from January 2019 to June 2025, covering adults ages 18 to 64 with type 2 diabetes and a BMI of 25 kg/m² or higher who had started on liraglutide (Victoza), semaglutide (Ozempic), or tirzepatide (Mounjaro). The lead author, Sainikhil Sontha, M.S., a research associate at Boston University School of Public Health, explained the two core questions: "How many people with type 2 diabetes taking GLP-1 medications actually stop using them? And how many restart them?"
The study found that the majority of people who discontinue GLP-1 medications eventually return to treatment. The mechanism driving return is documented in parallel research: weight regain is faster after stopping GLP-1 drugs than after nearly any other weight intervention.
A January 2026 meta-analysis published in the British Medical Journal — reviewed by the Washington Post — found that people who stop GLP-1 medications regain lost weight approximately four times faster than those who stopped conventional diet-and-exercise programs. The same paper found that former GLP-1 users were projected to return to their original weight within approximately 18 months of stopping. A March 2026 Cleveland Clinic real-world study, published in the journal Diabetes, Obesity and Metabolism, found that in the obesity treatment group, 55% of patients gained weight in the year after discontinuation — though 45% kept losing or maintained their weight, often by switching to alternative treatments.
| GLP-1 Discontinuation and Restart Data | Finding |
| Study design | Retrospective cohort, Komodo Health claims data (Jan 2019 – Jun 2025) |
| Data source | Boston University / ENDO 2026 presentation |
| GLP-1 drugs studied | Liraglutide, semaglutide, tirzepatide |
| Key finding | Majority of those who stop GLP-1s eventually restart |
| Weight regain rate after stopping | 4x faster than conventional dieting (BMJ, Jan 2026) |
| Time to full weight regain (projected) | ~18 months |
| Obesity patients who gained weight post-stop | 55% (Cleveland Clinic, March 2026) |
| Obesity patients who maintained or lost weight post-stop | 45% (Cleveland Clinic, March 2026) |
What the Restart Pattern Reveals About Obesity — and Why It Changes the Treatment Model
The pattern documented across these studies is not a failure of individual patients — it is evidence of how obesity actually works as a biological disease. When GLP-1 drugs suppress appetite by acting on the brain's satiety centers and slow gastric emptying, they are compensating for neurological and hormonal dysregulation that does not disappear when the drug is stopped. The hunger signaling pathways that GLP-1 drugs suppress — including the body's appetite-driving hormones ghrelin and peptide YY — return to their pre-treatment states relatively quickly after discontinuation. The biology reasserts itself. Weight comes back.
"Our study asked two questions that haven't been well answered until now: How many people with type 2 diabetes taking GLP-1 medications actually stop using them? And how many restart them?" Sainikhil Sontha told ENDO 2026 attendees. The clinical implication of the restart pattern is significant: if the majority of patients who stop GLP-1s eventually come back, then designing treatment programs around episodic short-term use — rather than chronic long-term management — may be setting patients up for the regain-and-restart cycle documented in this data.
This reframes GLP-1 medications alongside other chronic disease treatments — antihypertensives, statins, diabetes medications — rather than as curative courses of treatment like antibiotics. The Cleveland Clinic's Dr. Hamlet Gasoyan noted: "Our real-world data show that many patients who stop semaglutide or tirzepatide restart the medication or transition to another obesity treatment, which may explain why they regain less weight than in prior clinical trials." The patients most likely to maintain weight loss after stopping were those who transitioned immediately to another evidence-based treatment, including bariatric surgery or an alternative GLP-1.
What This Means for Patients — and What to Discuss With Your Doctor
For the estimated 28 million Americans who have used GLP-1 medications, this body of evidence creates a concrete framework for informed decision-making. Stopping a GLP-1 drug is not inherently wrong — many people stop due to cost, side effects, insurance coverage changes, or a planned break. But the data strongly suggest that stopping without a transition plan significantly increases the probability of rapid weight regain and metabolic deterioration.
A separate ENDO 2026 study, also reported by ScienceDaily, found that people with obesity who lost weight on GLP-1 drugs became significantly less physically active — a counterintuitive finding suggesting that medication-driven weight loss does not automatically produce the behavioral changes needed to maintain it independently. This reinforces the importance of building physical activity habits, nutritional structure, and behavioral health support during the period of drug use — not after stopping.
The EPA's and FDA's guidance on obesity treatment frames semaglutide and tirzepatide explicitly as chronic weight management medications — not short-term treatments. Patients who are considering stopping should discuss a structured exit plan with their physician, including whether transitioning to a different medication class, reducing to a lower maintenance dose, or pursuing a concurrent behavioral or endoscopic intervention might reduce the probability of rapid regain.
Frequently Asked Questions
Do most people regain weight after stopping Ozempic or Wegovy?
Multiple studies confirm this, including a January 2026 BMJ meta-analysis showing people regain weight four times faster after stopping GLP-1 drugs than after stopping conventional dieting, and a March 2026 Cleveland Clinic real-world study finding 55% of obesity patients gained weight in the year after stopping.
How quickly does weight come back after stopping GLP-1 drugs?
The BMJ analysis projected that former users were on pace to return to their original weight within approximately 18 months. Other studies have found that the majority of regain occurs within the first six months after stopping, particularly in patients who do not transition to another treatment or intensify behavioral interventions.
Do most GLP-1 users who stop eventually restart the medication?
The ENDO 2026 study presented by Sainikhil Sontha of Boston University School of Public Health, analyzing Komodo Health data covering millions of GLP-1 users with type 2 diabetes, found that the majority of those who discontinue GLP-1 medications eventually restart, primarily due to weight regain and worsening metabolic markers.
Is Ozempic meant to be taken long-term?
The FDA has approved semaglutide and tirzepatide explicitly as chronic weight management medications — comparable in concept to antihypertensives or statins. While they are not required to be taken indefinitely, the clinical evidence increasingly supports long-term use as necessary to maintain metabolic benefits for most patients.
What should I do if I want to stop my GLP-1 medication?
Talk to your physician before stopping. Discuss whether a dose reduction, a transition to an alternative treatment, or an intensified behavioral health plan is appropriate. The Cleveland Clinic's real-world data show that patients who transitioned to another treatment after stopping had significantly better weight maintenance outcomes than those who simply stopped without a plan.
